Radnostix Sells Nuclear Assets to NANO Nuclear for $13.5 Million
News related to:Radnostix, Inc · 3 min read
BOISE, Idaho, Oct. 1, 2026 /CourierPR/ -- Radnostix, Inc., formerly known as International Isotopes Inc., has signed a definitive agreement to divest its U.S. nuclear fuel processing assets, including a U.S. Nuclear Regulatory Commission (NRC) license and related intellectual property and technical materials, to NANO Nuclear Energy Inc. The assets, which include depleted uranium hexafluoride (DUF6) deconversion and fluorine extraction capabilities, are located in Lea County, New Mexico.
The transaction, which is expected to close in approximately 90 to 120 days, will see NANO Nuclear acquire these assets for a total consideration of $13.5 million. This includes $9.5 million in cash and $4 million in NANO common stock, payable and issuable at closing. The deal is subject to NRC consent to the license transfer, other required approvals and consents, satisfactory site arrangements, and other closing conditions.
Radnostix, established in 1995 with its headquarters in Idaho Falls, Idaho, manufactures a wide range of radioisotope technology products. The company supplies generic sodium iodide I-131 radio-pharmaceutical drug product for hyperthyroidism and thyroid cancer, as well as contract manufacturing of various drug products and radioisotope API supply for third-party theranostics clients. Radnostix also manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and SPECT/PET imaging systems under its RadQual brand.
Following the closing, Radnostix intends to utilize the net proceeds to accelerate the growth of its four radioisotope technology product segments through enhanced research and development and continued organic and inorganic growth initiatives. The company's focus will remain on its core radioisotope technologies, which include medical and industrial applications.
The transaction underscores the importance of the U.S. nuclear fuel cycle industry and the strategic alignment between Radnostix and NANO Nuclear. It also highlights the company's commitment to strengthening its balance sheet for the next chapter of its business. Radnostix, Inc. (INIS), established in 1995, with its headquarters in Idaho Falls, Idaho, manufactures a wide range of radioisotope technology products. The company supplies generic sodium iodide I-131 radio-pharmaceutical drug product for hyperthyroidism and thyroid cancer, as well as contract manufacturing of various drug products and radioisotope API supply for third-party theranostics clients. Radnostix also manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and SPECT/PET imaging systems under its RadQual brand.
The transaction is subject to NRC consent to the license transfer, other required approvals and consents, satisfactory site arrangements, and other closing conditions. The deal is expected to close in approximately 90 to 120 days, although the timing will depend on those approvals and conditions. Radnostix, Inc. (INIS), established in 1995, with its headquarters in Idaho Falls, Idaho, manufactures a wide range of radioisotope technology products. The company supplies generic sodium iodide I-131 radio-pharmaceutical drug product for hyperthyroidism and thyroid cancer, as well as contract manufacturing of various drug products and radioisotope API supply for third-party theranostics clients. Radnostix also manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and SPECT/PET imaging systems under its RadQual brand.
The transaction is subject to NRC consent to the license transfer, other required approvals and consents, satisfactory site arrangements, and other closing conditions. The deal is expected to close in approximately 90 to 120 days, although the timing will depend on those approvals and conditions. The transaction is subject to NRC consent to the license transfer, other required approvals and consents, satisfactory site arrangements, and other closing conditions. The deal is expected to close in approximately 90 to 120 days, although the timing will depend on those approvals and conditions.